These findings could help identify patients for risk assessment, cancer surveillance, and more focused management planning and education for RAD51C and RAD51D mutation carriers, as well as provide a hypothesis of the mechanistic role of RAD51D in carcinogenesis. This evidence concerns the gene RAD51D and cancer.